2:57 PM
 | 
Jun 14, 2019
 |  BC Extra  |  Preclinical News

June 13 Preclinical Quick Takes: A*STAR's mAb against tumor-displayed antigen; plus Columbia, Genentech and more

A*STAR targets externalized antigen to kill tumor cells
The Agency for Science Technology and Research has licensed PTP4A3-targeting cancer therapy PRL3-zumab to spinout company Intra-Immu SG Pte Ltd. (Singapore). A*STAR and colleagues reported in a Nature Communications paper the mAb directs immune cells to kill tumor cells that externally express the antigen in mice with liver cancer. PTP4A3, an intracellular enzyme, was displayed on the cell surface in tumor tissue but not adjacent normal tissues in patient samples covering 11 types of solid and blood cancers.

Columbia finds new integrase-based CRISPR system...

Read the full 442 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >